A US News and World Report article profiles a new test to determine the effectiveness of Alzheimer's drugs developed by Cure Alzheimer's Fund's Dr. David Holtzman. The stable isotope-linked kinetics or SILK test quickly reveals whether medication is working to limit the harmful protein amyloid beta.
Research Consortium member David Holtzman featured in US News and World Report
Posted: Jun. 29, 2009
© 2005-2016 Cure Alzheimer's Fund. All rights reserved.